Atorvastatin

證據等級: L5

預測適應症: 10 個

Atorvastatin: From Primary Hypercholesterolemia to Familial Hypercholesterolemia

Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

One-Sentence Summary

Atorvastatin is a synthetic HMG-CoA reductase inhibitor (statin) used globally as a cornerstone treatment for primary hypercholesterolemia and cardiovascular risk reduction, though no TGA ARTG registration data was retrieved in this analysis cycle. The TxGNN model predicts it may be effective for familial hypercholesterolemia (FH) — the genetically-driven form of severely elevated LDL cholesterol — reflecting mechanistic alignment with the drug’s core pharmacology. This prediction is backed by 34 clinical trials and 19 publications, representing one of the strongest evidence bases of any indication in this analysis.

Quick Overview

Item	Content
Original Indication	Not retrieved from ARTG (globally registered for primary hypercholesterolemia and mixed dyslipidaemia — see note below)
Predicted New Indication	Familial Hypercholesterolemia
TxGNN Prediction Score	99.42%
Evidence Level	L1
Australia Market Status	Not marketed (⚠️ likely data retrieval gap — see Australia Market Information section)
Number of ARTG Entries	0 (⚠️ verification required)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. By reducing endogenous cholesterol production, the liver compensatorily upregulates LDL receptor expression, accelerating clearance of circulating LDL-C from the bloodstream. This direct, well-characterised mechanism has made atorvastatin the most widely prescribed statin globally for over two decades, with dose-dependent reductions in total cholesterol, LDL-C, and triglycerides across a broad population.

Familial hypercholesterolemia is defined by inherited loss-of-function variants in the LDLR, APOB, or gain-of-function variants in PCSK9, all of which impair LDL clearance and drive severely elevated LDL-C from birth. Heterozygous FH (HeFH) patients — who retain partial LDL receptor function — typically achieve 40–50% LDL-C reduction with maximally tolerated atorvastatin doses and constitute the primary responder group. Homozygous FH (HoFH) patients, with near-absent receptor function, have attenuated statin response and generally require combination therapy (ezetimibe, PCSK9 inhibitors, lomitapide, or LDL apheresis). International guidelines (ESC/EAS, AACE/ACE) universally recommend high-intensity statins as first-line pharmacotherapy for both FH subtypes.

The TxGNN prediction score of 99.42% reflects the knowledge graph’s high-confidence linkage between atorvastatin’s pharmacological targets (HMGCR, LDL receptor pathway) and the molecular drivers of FH. Rather than representing a novel repurposing discovery, this result validates atorvastatin’s established clinical role within a genetically-defined patient subgroup — an important distinction for regulatory and reimbursement pathways in the Australian context.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00136981	Phase 3	Completed	800	24-month double-blind RCT comparing torcetrapib/atorvastatin vs atorvastatin alone in HeFH patients; used carotid intima-media thickness as primary atherosclerosis endpoint — largest direct atorvastatin RCT in FH
NCT03884452	Phase 3	Completed	50	Ezetimibe co-administered with atorvastatin or simvastatin in HoFH; established the evidence base for standard dual-agent combination therapy in the most severe FH subtype
NCT02107898	Phase 3	Completed	216	Double-blind RCT of alirocumab vs placebo added to stable statin (including atorvastatin) in HeFH or high-CVR patients; demonstrated significant LDL-C reduction at 24 weeks
NCT01623115	Phase 3	Completed	486	Double-blind RCT of alirocumab vs placebo on background atorvastatin in HeFH patients with LDL-C ≥160 mg/dL; supports atorvastatin as the backbone of combination lipid-lowering in FH
NCT01507831	Phase 3	Completed	2,341	Long-term safety of alirocumab in high-CVR patients on lipid-modifying therapy including atorvastatin; the largest enrolment trial in this evidence set, providing robust safety and efficacy data
NCT00827606	Phase 3	Completed	272	Three-year prospective open-label study of atorvastatin in children and adolescents (aged 6–17) with HeFH; characterised growth and development alongside LDL-C reduction over an extended paediatric timeframe
NCT01730040	Phase 3	Completed	355	Four-arm double-blind RCT comparing alirocumab add-on vs ezetimibe add-on vs atorvastatin dose increase vs switch to rosuvastatin in patients uncontrolled on atorvastatin; informs optimal treatment escalation strategy in HeFH
NCT03882996	Phase 3	Completed	432	Long-term (up to 12 months) safety and tolerability of ezetimibe added to atorvastatin 10–80 mg in HeFH or CHD patients not controlled on atorvastatin monotherapy
NCT00145574	Phase 4	Completed	194	RCT of colesevelam vs placebo in paediatric HeFH patients (aged 10–17) on stable statin monotherapy including atorvastatin; demonstrated additive LDL-C lowering with triple therapy
NCT06686615	N/A	Recruiting	2,000	Large-scale observational study of bempedoic acid + ezetimibe + atorvastatin or rosuvastatin in primary hypercholesterolaemia or mixed dyslipidaemia; will provide real-world combination effectiveness data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11058703	2000	Clinical Trial	Atherosclerosis	Atorvastatin at escalating doses (10–40 mg/day) evaluated in 9 HoFH patients on LDL apheresis; 5 of 9 responded well, with significant LDL-C and apolipoprotein B reduction — key early evidence in the most severe FH subtype
9793596	1998	Clinical Trial Review	Annals of Pharmacotherapy	Comprehensive early review of atorvastatin efficacy and safety across dyslipidemias; established dose-response relationships and positioned atorvastatin as the highest-potency statin for LDL-C reduction at launch
39751968	2025	Review	Current Atherosclerosis Reports	Up-to-date review of novel pharmacological therapies for HoFH; contextualises statins including atorvastatin alongside PCSK9 inhibitors, inclisiran, evinacumab and LDL apheresis in contemporary treatment algorithms
28437620	2017	Clinical Guideline	Endocrine Practice	AACE/ACE dyslipidaemia and cardiovascular prevention guidelines; endorses high-intensity statins as first-line in FH with LDL-C targets stratified by cardiovascular risk category
27417002	2016	Cohort Analysis	Journal of the American College of Cardiology	Quantified statin-induced reduction in coronary artery disease events and all-cause mortality in a large HeFH cohort; first robust real-world estimate of clinical event benefit from statins in FH
27678432	2016	Prospective Cohort	Journal of Clinical Lipidology	Three-year efficacy and safety of atorvastatin in children aged 6–17 with HeFH; confirmed sustained LDL-C reduction without adverse effects on growth, pubertal development or hepatic safety
9129869	1997	Review	Drugs	Foundational pharmacology review of atorvastatin; describes HMG-CoA reductase inhibition mechanism, prolonged half-life of active metabolites, and dose-dependent lipid effects relevant to FH dosing
26988948	2016	Review	Journal of the American College of Cardiology	Expert commentary on improving monitoring and care in FH patients; highlights under-diagnosis, under-treatment, and the critical role of statins as the therapeutic cornerstone
35361995	2022	Genomic Study	The Pharmacogenomics Journal	Novel NGS approach combining FH gene panel with pharmacogenomic statin response markers; demonstrates clinical utility of genotype-guided atorvastatin dosing in FH patients
32800790	2020	Case Report	Journal of Clinical Lipidology	Decade-long management of a child with compound heterozygous FH (presenting LDL-C 17.4 mmol/L); illustrates the evolution from bile acid sequestrants through atorvastatin combination therapy to PCSK9 inhibitors

Australia Market Information

⚠️ Data Retrieval Alert: This analysis returned 0 ARTG entries for atorvastatin. This is inconsistent with atorvastatin’s well-established global availability — it is widely marketed as Lipitor® (Pfizer) and multiple generic formulations and has been available in Australia for many years. This almost certainly reflects an incomplete data extraction rather than genuine absence from the Australian market.

Item	Detail
ARTG Entries Retrieved	0 (data extraction incomplete)
Expected Market Status	Marketed — Lipitor® (brand) and multiple TGA-registered generics
PBS Listing	Atorvastatin is listed on the PBS for hypercholesterolaemia and mixed dyslipidaemia (verification recommended for specific FH PBS criteria)
Action Required	Verify current ARTG entries via TGA ARTG Search and PBS Schedule for funded indications

Healthcare professionals should confirm ARTG numbers, approved indications and PBS subsidisation criteria — particularly whether FH as a specific genetic diagnosis carries distinct PBS eligibility requirements — directly through the TGA and Services Australia before clinical or prescribing decisions.

Safety Considerations

Detailed TGA-specific safety data (Product Information warnings and contraindications) was not retrieved in this analysis cycle.

Please refer to the TGA-approved Product Information (PI) for atorvastatin for complete safety information. Key safety areas to review include:

Musculoskeletal toxicity: Myopathy and rhabdomyolysis risk, particularly when combined with CYP3A4 inhibitors or other myotoxic agents
Hepatotoxicity: Baseline and periodic liver function monitoring requirements
Pregnancy and lactation: Atorvastatin is contraindicated in pregnancy (Pregnancy Category D in Australia) and breastfeeding
Drug–drug interactions: Atorvastatin is a CYP3A4 substrate — significant interactions include azole antifungals, macrolide antibiotics, HIV protease inhibitors (ritonavir, lopinavir), and colchicine; these interactions are particularly relevant if atorvastatin is considered as adjunct therapy in HIV patients (see Rank 2 predicted indication)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Atorvastatin has an exceptionally strong evidence base for familial hypercholesterolemia, including multiple completed Phase 3 RCTs with thousands of participants, endorsement as first-line therapy in all major international dyslipidaemia guidelines, and a direct mechanistic link to the genetic pathophysiology of FH. The L1 evidence classification is well-justified. The primary barriers to a straightforward “Go” decision in the Australian context are the unresolved TGA ARTG data retrieval issue and the absence of formal MOA documentation in this evidence pack.

To proceed, the following is needed:

ARTG verification (Priority: Blocking): Manually search the TGA ARTG database to confirm current registration status, approved indications, and listed dosage forms for atorvastatin in Australia; resolve the data retrieval failure
PBS criteria review: Confirm whether FH as a specific genetic or clinically-diagnosed condition carries distinct PBS subsidisation criteria beyond general hypercholesterolaemia — this affects access and cost for Australian patients
MOA formal documentation: Retrieve and record atorvastatin’s mechanism of action from DrugBank API (DB01076) to complete the evidence package — the mechanistic link to FH is clinically well-understood but must be formally captured for the repurposing dossier
FH subtype stratification: Specify the target patient population — HeFH (strong evidence, atorvastatin monotherapy often adequate at maximally tolerated doses) vs HoFH (evidence supports use but response is limited by residual LDL receptor function; combination therapy with ezetimibe and/or PCSK9 inhibitors is standard of care)
TGA PI safety extraction: Download and parse the TGA-approved Product Information PDF to populate the safety data fields (warnings, contraindications, interactions) currently flagged as data gaps
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.